Moderna (MRNA) Stock Price, News & Analysis

Company Overview

Moderna, Inc. is a biotechnology company that develops medicines and vaccines using messenger RNA (mRNA) technology. Its platform is designed to instruct cells to produce proteins that can stimulate immune responses or support the treatment of disease. The company’s research programs span infectious diseases, immuno-oncology, rare diseases, autoimmune conditions and other therapeutic areas.

Moderna’s commercial products include Spikevax, an mRNA vaccine for COVID-19, and mRESVIA, an mRNA vaccine for respiratory syncytial virus (RSV) in older adults. The company also maintains a pipeline of investigational vaccines and therapeutics, including programs targeting seasonal influenza, cytomegalovirus, combination respiratory infections and cancer-related applications.

Founded in 2010 and originally known as ModeRNA Therapeutics, Moderna is headquartered in Cambridge, Massachusetts. The company serves markets internationally through regulatory approvals, commercial partnerships and distribution arrangements. Stéphane Bancel has served as Moderna’s chief executive officer, while Noubar Afeyan is the company’s founder and chairman.

Key Stats

• Today's Range: $181.65 to $203.82
• 50-Day Range: $62.96 to $245.81
• 52-Week Range: $22.28 to $254.48
• Volume: 17.07 million shs
• Average Volume: 19.84 million shs
• Market Capitalization: $79.39 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $107.10
• Consensus Rating: Hold

Moderna Stock Analysis - MarketRank™

Moderna scored higher than 34% of companies evaluated by MarketBeat, and ranked 673rd out of 907 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 2.1 / 5
• Analyst Rating: Hold

Consensus Rating

Moderna has received a consensus rating of Hold. The company's average rating score is 2.12, and is based on no strong buy ratings, 7 buy ratings, 14 hold ratings, and 4 sell ratings.

Downside Risk

Moderna has a consensus price target of $107.10, representing about 46.1% downside from its current price of $198.85.

Amount of Analyst Coverage

Moderna has been the subject of 23 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Moderna are expected to grow in the coming year, from ($6.11) to ($4.53) per share.

Price to Book Value per Share Ratio

Moderna has a P/B Ratio of 8.98. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

9.16% of the float of Moderna has been sold short.

Short Interest Ratio / Days to Cover

Moderna has a short interest ratio ("days to cover") of 1.78, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Moderna has recently increased by 5.64%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Moderna does not currently pay a dividend.

Dividend Growth

Moderna does not have a long track record of dividend growth.

News and Social Media

• Score: 3.1 / 5
• News Sentiment: 0.01

News Sentiment

Moderna has a news sentiment score of 0.01. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.60 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 83 news articles for Moderna this week, compared to 9 articles on an average week.

Search Interest

78 people have searched for MRNA on MarketBeat in the last 30 days. This is an increase of 86% compared to the previous 30 days.

MarketBeat Follows

50 people have added Moderna to their MarketBeat watchlist in the last 30 days. This is an increase of 52% compared to the previous 30 days.

Company Ownership

• Score: 1.8 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Moderna insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $33,875,904.00 in company stock.

Percentage Held by Insiders

10.80% of the stock of Moderna is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

75.33% of the stock of Moderna is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 7/31/2026
• Today: 10/27/2026
• Next Earnings (Estimated): 11/06/2026
• Investor Day 2026: 11/12/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:MRNA
• CIK: 1682852
• Web: www.modernatx.com
• Phone: (617) 714-6500
• Fax: N/A
• Employees: 4,700
• Year Founded: 2010

Price Target and Rating

• Average Price Target for Moderna: $107.10
• High Price Target: $230.00
• Low Price Target: $17.00
• Potential Upside/Downside: -46.1%
• Consensus Rating: Hold
• Rating Score (0-4): 2.12
• Research Coverage: 25 Analysts

Profitability

• EPS (Trailing Twelve Months): ($7.99)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$2.82 billion
• Net Margins: -141.43%
• Pretax Margin: -138.55%
• Return on Equity: -28.30%
• Return on Assets: -19.39%

Debt

• Debt-to-Equity Ratio: 0.09
• Current Ratio: 2.29
• Quick Ratio: 2.18

Sales & Book Value

• Annual Sales: $1.94 billion
• Price / Sales: 40.84
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $22.14 per share
• Price / Book: 8.98

Miscellaneous

• Outstanding Shares: 399,240,000
• Free Float: 356,119,000
• Market Cap: $79.39 billion
• Optionable: Optionable
• Beta: 1.09